In current practice, surveillance for thyroid cancer recurrence currently relies on serum biomarkers (including thyroglobulin in differentiated thyroid cancer (DTC) and calcitonin in medullary thyroid cancer (MTC)), radiological screening and invasive biopsies. This evidence concerns the gene TG and thyroid cancer.